Azathioprine - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for azathioprine and what is the scope of freedom to operate?
Azathioprine
is the generic ingredient in four branded drugs marketed by Aaipharma Llc, Alkem Labs Ltd, Amneal, Rising, Zydus Pharms Usa, Sebela Ireland Ltd, Hikma, and Casper Pharma Llc, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.There are sixteen drug master file entries for azathioprine. Fifteen suppliers are listed for this compound.
Summary for azathioprine
US Patents: | 0 |
Tradenames: | 4 |
Applicants: | 8 |
NDAs: | 8 |
Drug Master File Entries: | 16 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 135 |
Clinical Trials: | 322 |
Patent Applications: | 7,483 |
Drug Prices: | Drug price trends for azathioprine |
What excipients (inactive ingredients) are in azathioprine? | azathioprine excipients list |
DailyMed Link: | azathioprine at DailyMed |
Recent Clinical Trials for azathioprine
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Henan Cancer Hospital | Phase 2 |
Tianjin Medical University Second Hospital | Phase 2 |
The Second Affiliated Hospital of Kunming Medical University | Phase 2 |
Pharmacology for azathioprine
Drug Class | Purine Antimetabolite |
Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for azathioprine
Anatomical Therapeutic Chemical (ATC) Classes for azathioprine
US Patents and Regulatory Information for azathioprine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus Pharms Usa | AZATHIOPRINE | azathioprine | TABLET;ORAL | 077621-002 | Sep 5, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Rising | AZATHIOPRINE | azathioprine | TABLET;ORAL | 075568-001 | Dec 13, 1999 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Zydus Pharms Usa | AZATHIOPRINE | azathioprine | TABLET;ORAL | 077621-003 | Sep 5, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for azathioprine
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Nova Laboratories Ireland Limited | Jayempi | azathioprine | EMEA/H/C/005055 Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. |
Authorised | no | no | no | 2021-06-21 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.